OPPM
Opus Point Partners Management Portfolio holdings
AUM
$46.9M
This Quarter Return
+18.25%
1 Year Return
-4.17%
3 Year Return
+83.22%
5 Year Return
+175.29%
10 Year Return
–
AUM
$150M
AUM Growth
+$150M
(+19%)
Cap. Flow
+$10.3M
Cap. Flow
% of AUM
6.88%
Top 10 Holdings %
Top 10 Hldgs %
43.11%
Holding
70
New
14
Increased
21
Reduced
14
Closed
12
Top Buys
| 1 |
Amgen
AMGN
|
$4.89M |
| 2 |
iShares Biotechnology ETF
IBB
|
$3.92M |
| 3 |
Gilead Sciences
GILD
|
$2.97M |
| 4 |
Bristol-Myers Squibb
BMY
|
$2.83M |
| 5 |
Merck
MRK
|
$2.59M |
Top Sells
| 1 |
Bio-Techne
TECH
|
$4.35M |
| 2 |
CPHD
Cepheid Inc
CPHD
|
$4.07M |
| 3 |
AstraZeneca
AZN
|
$2.95M |
| 4 |
Biogen
BIIB
|
$2.14M |
| 5 |
Mettler-Toledo International
MTD
|
$1.87M |
Sector Composition
| 1 | Healthcare | 83.31% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
iShares Biotechnology ETF
IBB
$5.6B
| $10.7M | 7.06% | 31,600 +11,600 | +58% | +$3.92M |
|
2
Alkermes
ALKS
$4.78B
| $6.94M | 4.58% | 87,415 +551 | +0.6% | +$43.7K |
|
3
Ionis Pharmaceuticals
IONS
$6.79B
| $6.35M | 4.19% | 102,459 +1,058 | +1% | +$65.5K |
|
|
ALXN
4
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $6.29M | 4.15% | 32,969 -52 | -0.2% | -$9.92K |
|
5
Nektar Therapeutics
NKTR
$568M
| $5.87M | 3.88% | 348,583 -95,675 | -22% | -$1.61M |
|
6
Regeneron Pharmaceuticals
REGN
$61.5B
| $5.82M | 3.84% | 10,714 +87 | +0.8% | +$47.2K |
|
|
7
Amgen
AMGN
$155B
| $5.81M | 3.84% | 35,773 +30,147 | +536% | +$4.89M |
|
|
CELG
8
DELISTED
Celgene Corp
CELG
| $5.74M | 3.79% | 47,956 +819 | +2% | +$98.1K |
|
|
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
| $5.7M | 3.77% | 127,088 +2,530 | +2% | +$114K |
|
|
10
Bristol-Myers Squibb
BMY
$96B
| $5.3M | 3.5% | 77,100 +41,100 | +114% | +$2.83M |
|
11
Vertex Pharmaceuticals
VRTX
$100B
| $5.24M | 3.46% | 41,662 +786 | +2% | +$98.9K |
|
12
Incyte
INCY
$16.5B
| $5.21M | 3.44% | 48,045 +645 | +1% | +$69.9K |
|
|
13
Merck
MRK
$210B
| $4.75M | 3.14% | 90,000 +49,000 | +120% | +$2.59M |
|
14
Alnylam Pharmaceuticals
ALNY
$58.5B
| $4.73M | 3.12% | 50,222 +1,774 | +4% | +$167K |
|
15
BioMarin Pharmaceuticals
BMRN
$11.2B
| $4.6M | 3.04% | 43,870 +1,858 | +4% | +$195K |
|
|
QGENF
16
DELISTED
QIAGEN NV
QGENF
| $4.42M | 2.92% | 160,000 | – | – |
|
|
MDVN
17
DELISTED
MEDIVATION, INC.
MDVN
| $4.41M | 2.92% | 91,310 -27,062 | -23% | -$1.31M |
|
18
Illumina
ILMN
$15.8B
| $4.35M | 2.87% | 22,643 -5,691 | -20% | -$1.09M |
|
|
19
Gilead Sciences
GILD
$140B
| $3.41M | 2.25% | 33,700 +29,377 | +680% | +$2.97M |
|
|
20
Mettler-Toledo International
MTD
$26.8B
| $3.29M | 2.17% | 9,700 -5,500 | -36% | -$1.87M |
|
|
21
Biogen
BIIB
$19.4B
| $3.21M | 2.12% | 10,482 -6,985 | -40% | -$2.14M |
|
|
ADMS
22
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $2.27M | 1.5% | +80,000 | New | +$2.27M |
|
23
Agios Pharmaceuticals
AGIO
$2.19B
| $2.21M | 1.46% | 34,000 -12,000 | -26% | -$779K |
|
|
EPZM
24
DELISTED
Epizyme, Inc
EPZM
| $2.17M | 1.44% | 135,627 +89,548 | +194% | +$1.43M |
|
25
Hologic
HOLX
$14.9B
| $1.86M | 1.23% | 48,000 | – | – |
|